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Low specificity of PGP9.5 expression for detection of
micrometastatic neuroblastoma
J Gilbert, MD Norris, GM Marshall and M Haber
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Summary To determine the specificity of neuroendocrine protein gene product (PGP9.5) gene transcripts for detecting micrometastatic
neuroblastoma, we have used a highly sensitive polymerase chain reaction (PCR) technique to evaluate expression of this gene in normal
blood and bone marrow. While expression of the tyrosine hydroxylase gene was not detected in any normal sample, low-level PGP9.5
expression was detected in eight out of ten blood and seven of 12 marrow samples. PGP9.5 gene transcripts in normal tissues have the
potential to interfere with the detection of micrometastatic neuroblastoma.
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Neuroblastoma is the most common solid tumourofyoung children.
Despite intensive combination chemotherapy, survival for advanced
stage disease remains poor, with a high proportion of patients
suffering bone marrow relapse (Brodeur and Castleberry, 1993).
The early detection ofresidual neuroblastoma cells in the peripheral
blood or bone marrow of such patients offers the potential of
predicting subsequent relapse, and would have immediate clinical
implications for patient management (Moss and Sanders, 1990). In
addition, the detection of circulating tumour cells in blood or
micrometastases in bone marrow before therapy may also provide
valuable information for the diagnosis and staging ofthis disease.
One of the most sensitive methods for detecting small numbers
of tumour cells involves the use of reverse transcription-poly-
merase chain reaction (RT-PCR) to amplify tumour-specific gene
transcripts (Datta et al, 1994; Betz et al, 1995; Foss et al, 1995;
Ghossein et al, 1995; Mori et al, 1995). Preliminary studies on
neuroblastoma have suggested two possible target genes for this
purpose, namely tyrosine hydroxylase (Naito et al, 1991; Burchill
et al, 1994, 1995; Miyajima et al, 1995) and neuroendocrine protein
gene product PGP9.5 (Mattano et al, 1992; Butturini et al, 1996).
Neuroblastoma cells are specifically characterized by secretion of
catecholamines, and tyrosine hydroxylase is the first and rate-
limiting enzyme in the catecholamine biosynthetic pathway.
PGP9.5 is aubiquitin carboxy-terminal hydrolase the expression of
which has been reported to be primarily restricted to cells of
neuroectodermal origin (Thompson et al, 1983; Wilson etal, 1988).
In order to exclude the likelihood of generating falsely positive
results when detecting micrometastatic disease by RT-PCR, it is
important that the target gene is not expressed in non-neoplastic
cells of the tissues being analysed. Low-level target gene expres-
sion by normal cells has the potential to interfere with occult
disease detection, and there have been a number of recent reports
indicating that particular target genes previously believed to be
tumour specific are in fact expressed in normal tissues. For
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example, Krismann et al (1995) have recently reported a significant
number offalse-positive results for RT-PCR analysis ofcytokeratin
19 mRNA expression in samples of normal peripheral blood,
although this gene has been proposed for detection ofoccult breast
and prostate cancer metastases (Wood et al, 1993 Datta et al, 1994).
Likewise, although prostate-specific antigen mRNA and MUC1
mRNA have been used for PCR detection of prostate and breast
micrometastases, respectively (Noguchi et al, 1994; Ghossein et al,
1995), recent reports have demonstrated expression of prostate-
specific antigen in cells of non-prostate origin (Smith et al, 1995),
and MUCI expression in non-neoplastic lymph nodes (Hoon et al,
1995). In view ofthese findings, we have employed a highly sensi-
tive 'nested' RT-PCR assay in order to evaluate the expression of
tyrosine hydroxylase and PGP9.5 in a range of normal blood and
bone marrow samples. The results showed PGP9.5 transcripts
present at low but clearly detectable levels in both normal blood
and marrow specimens, while tyrosine hydroxylase expression was
undetectable in all cases. These findings suggest caution should be
used in employing PGP9.5 for micrometastatic disease detection.
MATERIALS AND METHODS
Cell lines and tissue samples
The neuroblastoma cell line, BE(2)-C, generously supplied by DrJ
Biedler (Memorial Sloan-Kettering Cancer Center, NY, USA),
was maintained as a monolayer culture at 37°C in RPMI-1640
medium supplemented with L-glutamine (2 mM) and 10% fetal calf
serum. Samples of normal blood were obtained from healthy
volunteers. Samples of normal bone marrow were obtained either
from healthy bone marrow donors or from patients presenting with
non-malignant disease.
RT-PCR
Total cellular RNA was isolated from tissues and cultured cells
using the method of Chomczynski and Sacchi (1987) and cDNA
was reverse transcribed using Moloney murine leukaemia virus
reverse transcriptase from 2-gg aliquots using random hexanu-
cleotide primers, essentially as described by Noonan et al, (1990).
Approximately one-fifth of this cDNA mixture was subjected to a
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Table 1 Oligonucleotide sequences used for RT-PCR analysis of gene expression
Primer Sense Antisense Product size (bp)
Tyrosine hydroxylase (outer) 5'-ACCMGTTCGACCCTGACCTGGAC-3' 5'-CCCTTCAGCGTGGTGTAGACCTCC-3' 182
Tyrosine hydroxylase (inner) 5'-CCCTGACCTGGACTTGGACCACCC-3' 5'-TCTCCTCGGCGGTGTACTCCACAC-3' 134
PGP9.5 (outer) 5'-CTGGGATTTGAGGATGGATC-3' 5'-ACACCTTGGCAGCGTCCTTC-3' 286
PGP9.5 (inner) 5'-GCCAATGTCGGGTAGATGAC-3' 5'-CAGCGTCCTTCAGCAGGGTG-3' 144
GAPDH 5'-TGGGGAAGGTGAAGGTCGGA-3' 5'-GAAGGGGTCATTGATGGCM-3' 110
TH_B
PGP9.5-P
GAPDH _p
GAPDH -a
Figure 1 Nested RT-PCR analysis oftyrosine hydroxylase and PGP9.5 expression in (A) BE(2)-C cells (lane 1), and ten samples of peripheral blood from normal
patients (lanes 2-11); and (B) BE(2)-C cells (lane 1), and 12 samples of normal bone marrow (lanes 2-13). Results presented are those obtained following the second
round of PCR. A single round of PCR, using primers specific for the GAPDH gene, was performed to confirm the integrity of all cDNA samples. W, watercontrol
first round of PCR for 35 cycles in a final volume of 25 p1 using 1
unit ofAmpliTaq Polymerase. Following an initial denaturation step
of3 min at94°C, each cycle consistedofdenaturation at94°Cfor45
s, primer annealing at 55°C for 45 s and primer extension at 72°C
for90 s. Owing to thehigh guanine and cytosine content ofthe tyro-
sine hydroxylase gene, the annealing temperature for PCR reactions
amplifying this gene was increased to 72°C. Primer pairs (Table 1),
both forthis initial roundofPCR ('outer' primers) andforthe subse-
quent second round of PCR ('inner' primers), were selected on the
basis that they spanned an intron-exon boundary and were tested to
ensure that they did not amplify genomic DNA. Integrity ofcDNA
samples was assessed by independently amplifying acontrol glycer-
aldehyde-3'-phosphate dehydrogenase (GAPDH) gene sequence for
35 cycles, as described above. To ensure sensitivity in detecting
target gene sequences, a second 'nested' round of PCR (30 cycles)
was performed using gene-specific primers internal to those used in
the first round (Table 1). The template forthis second round ofPCR
was a 1-,ul aliquot of the first round reaction mix. Following PCR,
aliquots (10 ,ul) were subjected to electrophoresis on 12% polyacry-
lamide gels before ethidium bromide staining, UV transillumination
and photography. Direct cycle sequencing (finol DNA Sequencing
System, Promega) of PCR products confirmed specific amplifica-
tion ofthe target genes.
RESULTS
In order to determine the specificity of tyrosine hydroxylase and
PGP9.5 transcripts for neuroblastoma, expression of these target
genes was evaluated in a panel often normal peripheral blood and
12 normal bone marrow samples using highly sensitive nested
PCR analysis. Expression of neither the tyrosine hydroxylase nor
PGP9.5 genes was detectable in these normal samples aftera single
round of PCR (data not shown). The results obtained with the
peripheral blood samples following the second round of PCR are
shown in Figure IA. Although expression oftyrosine hydroxylase
was clearly detectable in the BE(2)-C neuroblastoma cells (lane 1),
no expression of this gene was detectable in any of the normal
blood samples (lanes 2-11). In contrast, expression ofPGP9.5 was
clearly detectable, notonly in BE(2)-C cells, butalso in eight ofthe
ten normal blood samples. Analysis by nested PCR of the target
genes in 12 normal bone marrow samples confirmed the high
specificity of tyrosine hydroxylase gene expression (Figure 1B).
Following the second round of PCR, expression of this gene was
present in the positive control BE(2)-C cDNA (lane 1) but not in
any ofthe normal marrow samples (lanes 2-13). PGP9.5, however,
was found to be expressed in seven of 12 normal bone marrow
samples, confirming the non-specific pattern of expression of this
gene observed with the peripheral blood samples. For all these
samples, the presence of intact cDNA was confirmed by PCR
amplification ofthe control GAPDH gene sequence.
DISCUSSION
A number of preliminary studies have indicated that PCR-based
analysis of neuroblastoma-associated gene transcripts might be
useful in improving the detection ofmicrometastatic disease either
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at diagnosis or following therapy (Naito et al, 1991; Burchill et al,
1994, 1995; Miyajima et al, 1995). Any potential target gene used
for this purpose must have high specificity, since this type ofassay
ultimately must be capable of detecting a few tumour gene tran-
scripts against a background of non-tumour mRNAs. The results
of the present study, using nested PCR, confirm other reports
demonstrating the highly specific pattern ofexpression ofthe tyro-
sine hydroxylase gene. Expression of PGP9.5, however, was
detectable in approximately 70% of normal blood and bone
marrow samples suggesting that this gene lacks the necessary
specificity for use as a target gene in detecting small numbers of
neuroblastoma cells. Similar conclusions have recently been
reached by other investigators in respect of genes whose expres-
sion was hitherto thought to be specific to tumours of breast and
prostate (Smith et al, 1995; Krismann et al, 1995; Hoon et al,
1995). Although the detection of PGP9.5 expression in normal
tissues could presumably be reduced or eliminated by using only a
single round of PCR, or by reducing the number of PCR cycles,
such manipulations would, ofnecessity, reduce the sensitivity with
which the target tumour cells could also be detected. Since
maximal sensitivity is required to avoid the possibility of biolog-
ical false-negative results (Smith et al, 1995), such manipulations
are undesirable, and the use of target genes that are not expressed
in normal tissues is clearly preferable.
Earlier studies have suggested that the increased sensitivity attrib-
utable to PCR could be used to detect the expression of otherwise
tissue-specific genes in any cell type (Chelly et al, 1989; Sarkar et
al, 1989). Chelly et al (1989) have described this form of gene
expression as 'illegitimate' transcription, since the level of expres-
sion is very low and unlikely to play any significant biological role.
Nevertheless, despite the use ofhighly sensitive nested PCR, illegit-
imate transcription oftyrosine hydroxylase expression could not be
detected in 22 blood and bone marrow specimens from normal
donors, suggesting that the gene is under tight regulatory control.
This finding is consistent with tyrosine hydroxylase being the rate-
limiting enzyme of the catecholamine biosynthetic pathway. Thus,
these findings confirm the suitability of tyrosine hydroxylase gene
expression for studies involving the PCR-based detection of
micrometastatic neuroblastoma in blood and bone marrow. In
contrast, positive results obtained following the use of PGP9.5 as
the target gene should be interpreted with caution given the frequent
expression ofthis gene in normal cells ofhaematopoietic origin.
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